Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
26,150
+100 (0.38%)
Aug 28, 2025, 3:30 PM KST
0.38%
Market Cap550.96B
Revenue (ttm)20.88B
Net Income (ttm)-8.83B
Shares Out21.07M
EPS (ttm)-675.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume73,923
Average Volume149,809
Open26,150
Previous Close26,050
Day's Range25,850 - 26,450
52-Week Range15,950 - 42,250
Betan/a
RSI63.01
Earnings DateAug 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 20
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.